11 assets in Wilson Disease

Therapeutic assets addressing Wilson Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Teta 4Hcl Wilson Disease	Orphalan	P3	BBB (73)
Zinc D-Gluconate (1:2) Wilson Disease	Jun Li	P4	BBB (72)
Penicillamine Wilson Disease	Orphalan	P3	BB (69)
Alxn1840 Wilson Disease	Alexion Pharmaceuticals, Inc.	P3	BB (66)
Gandouling Wilson Disease	Jun Li	P4	BB (65)
Ly-M003 Wilson Disease	Lingyi Biotech Co., Ltd.	P1/2	CCC (54)
Capsomere, Recombinant Human Adeno-Associated Virus Aav3B Viral Capsid Protein Vp1-Vp2-Vp3 Complex (1:2:7), Hexacontamer, Complex With Dna (Recombinant Replication-Defective Adeno-Associated Virus Serotype 3B Vector Vtx-801 Liver-Specific Human ?-1 Antitrypsin Promoter Plus Human 57-486-Copper Transporter Atp7B Codon-Optimized Gene Plus Rabbit ?-Globin Polyadenylation Signal Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) (1:1) Wilson Disease	Vivet Therapeutics SAS	P1/2	CCC (48)
Dna (Recombinant Replication-Defective Adeno-Associated Virus Serotype 9 Vector Ux701 Murine Transthyretin Enhancer Plus Human Transthyretin Promoter Plus Simian Virus 40 Intron Plus Human Adenosine Triphosphatase Copper-Transporting ? Metal-Binding Domain 4/5/6 Transgene Atp7B-Mbd456 Plus Simian Virus 40 Polyadenylation Signal Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks Plus Adeno-Associated Virus 2 Rep Region Plus Adeno-Associated Virus 9 Cap Region-Specifying) Wilson Disease	Ultragenyx Pharmaceutical Inc	P1/2	CC (47)
DSL101 Wilson Disease	DSciLab Co., Ltd.	Early P1	C (39)
gc310 Wilson Disease	GeneCradle Inc	P1/2	NR ()
Mwav201 Wilson Disease	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	N/A	NR ()